Contraception in women with vascular risk;Contraception chez la femme a risque vasculaire

Medecine Therapeutique

Volumn 6, Issue 6, 2000, Pages 474-486

  Galand Portier, M B ^a   Plu Bureau, G ^a   Touraine, P ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS LYNESTRENOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; MESTRANOL PLUS NORETHISTERONE; MINESSE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLANOR; SPERMICIDAL AGENT;

ARTERIAL PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CONDOM; DIABETES MELLITUS; DRUG MECHANISM; DYSLIPIDEMIA; FEMALE; GLUCOSE METABOLISM; HEART INFARCTION; HEART PROTECTION; HEMOSTASIS; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LIPID METABOLISM; MIGRAINE; ORAL CONTRACEPTION; REVIEW; TREATMENT CONTRAINDICATION; VEIN THROMBOSIS;

EID: 0033866184     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Contraception hormonale feminine
2. Haemostatic, lipid and blood-pressure profiles of women on oral contraceptives containing 50 μg or 30 μg estrogen
3. Coagulation and anti-coagulation effects of contraceptive steroids
4. Effects of oral contraceptives on hemostasis and thrombosis
5. Changes in haemostatic variables induced by oral contraceptives containing 50 μg or 30 μg oestrogen: Absence of dose-dependent effect on PAI-1 activity
6. Hemostatic and metabolic effects of lowering the ethinyloestradiol dose from 30 μg to 20 μg in oral contraceptive containing desogestrel
7. Plasma fibrinogen: An independent cardiovascular risk factor
8. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Health Study
9. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivor of myocardial infarction
10. Effect of long term use of Norplant implants on hemostatic function
11. Oral contraceptives and coagulation
12. Blood coagulation with a combination pill containing gestodene and ethinyl estradiol
13. Hemostasis in oral contraception: The role of progestogens
14. Steroids and lipid metabolism: Mechanism of action
15. Effect of oestrogen/progestin potency on lipid/lipoprotein cholesterol
16. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism
17. Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk
18. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: A controlled, comparative 12-month clinical trial
19. Effects of oral contraceptives on lipid metabolism
20. Insulin resistance, secretion and metabolism in users of oral contraceptives
21. Relationship between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1
22. Contraceptive Steroids and coronary artery atherosclerosis in cynomolgus macaqus
23. Oral contraceptives lipoproteins and atherosclerosis
24. Oral contraceptives and rheumatoid arthritis: Results from a primary care-based incident case-control study
25. When the pill causes a rise in blood pressure
26. Regression analysis of changes in blood pressure with oral contraceptive use
27. Oral contraceptives and blood pressure
28. Oral contraceptives and hypertension
29. Malignant hypertension in women of childbearing age and its relation to the contraceptive pills
30. Oral contraceptives and health
31. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestagen
32. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease
33. Low-dose oral contraception and blood pressure in women with a past history of elevated blood pressure
34. Estrogen improves endothelium dependent, flow mediated vasodilatation in post menauposal women
35. Estrogen and inhibition of oxidation of low-density lipoproteins in post menopausal women
36. 17β-Estradiol stimulates prostacyclin but not endothelin production in human vascular endothelial cells
37. Epidemiology of oral contraceptives and cardiovascular disease
38. Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study. WHO collaborative study of cardiovascular disease and steroid hormone contraception
39. Oral contraception and myocardial infarction revisited: The effect of new preparation and prescribing patterns
40. Cardiovascular disease and use of oral contraceptive
41. Oral contraceptive use and risk of myocardial infarction: An italian case-control study
42. Oral contraceptive use and the risk of myocardial infarction
43. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study
44. Smoking and use of oral contraceptives: Impact on thrombotic diseases
45. Oral contraceptives and myocardial infarction: Results of the MICA case-control study
46. Risk factors for acute myocardial infarction in Copenhagen: Smoking, alcohol intake, physical activity, obesity, oral contraception, diabetes, lipids and blood pressure
47. Cardiovascular death among women under 40 years of age using low-dose oral contraceptives and intrauterine devices in Finland from 1975 to 1984
48. Third generation oral contraceptives and risk of myocardial infarction: An international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women
49. Risk of acute myocardial infarction and low-dose oral contraceptives
50. The use of oral contraceptives and the occurence of acute myocardial infarction in young women. Transnational Research Group on Oral Contraceptives and the Health of Young Women
51. Past use of oral contraceptives and cardiovascular disease: A meta-analysis in the context of the Nurse's Health Study
52. Oral contraception and stroke. Evidence from the Royal College of General Practitioners' Oral contraception study
53. Stroke in users of low-dose oral contraceptives
54. Haemorrhagic stroke, overall stroke risk anti combined oral contraceptives: Results of an international, multicentre, case-control study. WHO collaborative study of cardiovascular disease and steroid hormone contraception
55. Fatal stroke and use of oral contraceptives: Findings from a case-control study
56. Subarachnoid hemorrhage and hormonal factors in women. A population-based case-control study
57. Oral contraception and the risk of a cerebral thromboembolic attack: Results of a case-control study
58. Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study. WHO collaborative study of cardiovascular disease and steroid hormone contraception
59. Case-control study of migraine anti risk of ischaemic stroke in young women
60. Risk factors for fatal venous thromboembolism in young women: A case-control study
61. Increased risk of venous thromboembolism in oral contraceptives users who are carriers of factor V Leiden mutation
62. Hyperhomocyst(e)inemia anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives
63. Oral contraceptives and non fatal cardiovascular disease
64. Oral contraceptive estrogen dose and the risk of deep venous thromboembolitic disease
65. Third generation oral contraceptives and venous thromboembolic disorders: An international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women
66. Venous thromboembolic disease and combined oral contraceptives: Results of an international multicentre case-control study
67. Risk of idiopathic cardiovascular death and non fatal venous thromboembolism in women using oral contraceptives with differing progestagen components
68. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
69. Venous thromboembolism among new users of different oral contraceptives
70. Oral contraceptives and venous thrombosis: Different sensitivitis to activated protein C in women using second- and third-generation oral contraceptives
71. Effects of oral contraceptives on hemostasis and thrombosis
72. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
73. AT III content and anti-thrombin activity in estrogen-progestogen and progestogen only treated women
74. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptive. Results of an international multicentre, case-control study
75. Oral progestogen-only contraceptives and cardiovascular risk: Results from the Transnational Study on Oral Contraceptives and the health of young women
76. Effets metaboliques et hormonaux de l'administration de 10 mg/jour de promegestone (R5020)
77. Effects of nomegestrol acetate (5 mg/d) on hormonal metabolic and hemostatic parameters in premenopausal women
78. Effects of cyproterone acetate on blood pressure, metabolic parameters and haemostasis in hirsute women
79. Contraception progestative par l'acetate de chlormadinone chez des femmes a risque vasculaire: Etude gyneco-endocrinienne, metabolique et vasculaire
80. Hormones et lupus
81. Oral contraceptives in systemic lupus erythematosus: Side effects and influence on the activity of SLE
82. Hormonal modulation in systemic lupus erythematosus: Preliminary clinical and hormonal results with cyproterone acetate
83. Contraceptions chez des femmes ayant une contre-indication aux oestroprogestatifs
84. Contraception des maladies a risque thrombo-embolique
85. Considerations for contraception in women with cardiovascular disorders
86. Contraception guidance in women with pre-existing disturbances in carbohydrate metabolism
87. Contraception for women with diabetes: An update
88. Oral contraceptives in women with diabetes
89. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus
90. Mortality and hormone-related exposures in women with diabetes
91. Pregnancy and contraception in the diabetic woman. Gestational diabetes. Recommendations of ALFEDIAM
92. Contraception in diabetic women
93. Consequences of intrauterine contraception in diabetic women
94. The copper T380A intrauterine device in women with type II diabetes mellitus
95. Peut-on prescrire la pilule contraceptive a la femme hyperlipidemique?
96. Hyperlipidemies et pilule contraceptive
97. Contraception and dyslipidemia
98. Report of the National cholesterol education Program-expert panel on detection, evaluation and treatment of high blood cholesterol in adults
99. The pill and mortality- An overview
100. Risks of oral contraceptive use in women over 35?
101. Use of oral contraceptives in patients with migraine
102. Oral contraceptive use and mortality during the 12 years of follow-up: The Nurses' Health Study
103. Migraine and stroke in young women: Case-control study. WHO collaborative study of cardiovascular disease and steroid hormone contraception